Sensible Biotechnologies
sensible.bio
Actively hiring
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$4.2M
1 round on record
Latest round
$4.2M
Pre-Seed · Apr 2023 · 3 yr ago
Backers
4
Y Combinator, Backed VC
The money's age
Long since its last round
41 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Pre-Seed | Apr 2023 | $4.2M | — | wgno.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator 
Backed VC 
BlueYard Capital 
Kaya VC Similar startupsby what they do, their industry and backers
艾博生物成立于2019年1月，是一家专注于信使核糖核酸（mRNA）药物研发的临床期创新型生物医药公司，拥有业界领先并具有自主知识产权的mRNA和纳米递送技术平台。公司已建立了丰富的产品管线，涵盖传染病防治和肿瘤免疫等领域。.
We develop transformative mRNA therapies by leveraging our ground-breaking proprietary delivery technology, machine learning and superior…
Elevated mRNA for transformative medicines. mRNA has already changed medicine. But the next generation of mRNA medicines – therapies that…
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
Asimov builds tools to program living cells. We're integrating mammalian synthetic biology with computer-aided design to advance…
News
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia, July 09, 2025--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic mRNA.
Read more
Report
Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology
BOSTON, June 12, 2025--Sensible Biotechnologies are accelerating the development of their cell-based platform for next-generation mRNA medicines with NVIDIA AI.
Read more
Report
mRNA Platform Company Sensible Biotechnologies Secures $4.2 Million
mRNA platform company Sensible Biotechnologies has announced a $4.2 million pre-seed round to accelerate the development of its cell-based platform for cost-efficient manufacturing of high-quality mRNA.
Read more
Report
Sensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing Round to Revolutionize mRNA Manufacturing
Read more
Report
Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform
mRNA technology has the potential to help develop many life-saving therapeutics and vaccines.
Read more
Report
Pro access
Upgrade to see all 6 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$4.2M
Latest round
Pre-Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Pre-Seed | 2023 | $4.2M | Details |